Targeted Lapatinib Anti-Her2/ErbB2 Therapy Resistance in Breast Cancer: Opportunities to Overcome a Difficult Problem

doi 10.20517/cdr.2019.92
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OAE Publishing Inc.

Related search

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

BioPATH: A Biomarker Study in Asian Patients With HER2+ Advanced Breast Cancer Treated With Lapatinib and Other Anti-Her2 Therapy

Cancer Research and Treatment
Cancer ResearchOncology
2019English

HER2-positive Breast Cancer With Brain Metastasis, Long Responder to Lapatinib Therapy

AboutOpen
2018English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Targeted Therapy for HER2 Positive Breast Cancer

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

Clinical Medicine Insights: Oncology
Oncology
2016English

Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Cancer Research
Cancer ResearchOncology
2017English

An Insertion Mutation of ERBB2 Enhances Breast Cancer Cell Growth and Confers Resistance to Lapatinib Through AKT Signaling Pathway

Biology Open
BiochemistryAgriculturalGeneticsMolecular BiologyBiological Sciences
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy